Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CRACR2A | Q9BSW2 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.46 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.46 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2784228 | 0.83 | KDM4E (0.42) | LMNAKDM4ERAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7972108 | 0.76 | LMNA (0.84) | LMNAKDM4ERAB9AMEN1KMT2A | |
| SCHEMBL7043652 | 0.75 | LMNA (1.00) | LMNAKDM4ERAB9AMEN1KMT2A | |
| SCHEMBL8297617 | 0.74 | RAB9A (0.51) | LMNAKDM4ERAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6621449 | 0.73 | LMNA (0.77) | LMNAKDM4ERAB9AMEN1KMT2A | |
| SCHEMBL16810760 | 0.72 | MAPT (0.47) | KDM4ERAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7043860 | 0.72 | LMNA (0.67) | LMNAKDM4ERAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7718022 | 0.70 | LMNA (0.73) | LMNAKDM4ERAB9AMEN1KMT2A | |
| SCHEMBL15216430 | 0.70 | LMNA (0.73) | LMNAKDM4ERAB9AMEN1KMT2A | |
| SCHEMBL8260401 | 0.70 | LMNA (0.57) | LMNAKDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | claimed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | claimed |
| CN-1826121-B | Application of phenyl and pyridyl derivatives in preparation of drugs for regulating calcium ion release and activating calcium ion channels | SYNTA PHARMACEUTICALS CORP | 2013-05-29 | — | — | CN | claimed |
| CN-102793692-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP | 2012-11-28 | — | — | CN | claimed |
| CN-101947218-A | The method of modulating calcium ion-release-activated calcium ion channels | SYNTA PHARMACEUTICALS CORP | 2011-01-19 | — | — | CN | claimed |
| EP-1651232-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2010-12-22 | — | — | EP | claimed |
| EP-1651232-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2007-06-06 | — | — | EP | claimed |
| EP-1653968-A4 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-06 | — | — | EP | claimed |
| CN-1826121-A | Method for regulating and controlling calcium ion release to activate calcium ion channel | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | claimed |
| CN-1826120-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | claimed |
| EP-1653968-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | Synta Pharmaceuticals Corporation (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1651232-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | claimed |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | SYNTA PHARMACEUTICALS CORP. | 2005-07-07 | — | — | US | claimed |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2005-05-19 | — | — | US | claimed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | LMNA 1685/4885KDM4E 2452/4885RAB9A 1725/4885 |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | ORAI1, CACNA1C, CACNA1F | LMNA 225/4885KDM4E 1800/4885RAB9A 841/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | LMNA 1685/4885KDM4E 2452/4885RAB9A 1725/4885 |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | TPMT, PTPN3, FKBP3 | LMNA 3048/4885KDM4E 1282/4885RAB9A 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.